Bain Capital Life Sciences Investors, LLC Xilio Therapeutics, Inc. Transaction History
Bain Capital Life Sciences Investors, LLC
- $312 Million
- Q3 2025
A detailed history of Bain Capital Life Sciences Investors, LLC transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Bain Capital Life Sciences Investors, LLC holds 4,566,817 shares of XLO stock, worth $3.2 Million. This represents 1.25% of its overall portfolio holdings.
Number of Shares
4,566,817
Previous 4,566,817
-0.0%
Holding current value
$3.2 Million
Previous $3.11 Million
24.99%
% of portfolio
1.25%
Previous 0.93%
Shares
3 transactions
Others Institutions Holding XLO
# of Institutions
35Shares Held
11MCall Options Held
0Put Options Held
0-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.01 Million16.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$878,9840.0% of portfolio
-
Morgan Stanley New York, NY962KShares$673,3410.0% of portfolio
-
Aju Ib Investment Co., Ltd. Seoul, M5668KShares$467,4190.49% of portfolio
-
Geode Capital Management, LLC Boston, MA329KShares$230,2800.0% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $19.2M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...